Menopause & Hormone Replacement Therapy (HRT) in Newport Beach — Evidence-Based Guide (2026) | Broad Medical Group (949) 720-9848
STRAW+10 Staging HRT Candidacy Risk & Benefit Treatment Options Monitoring Duration FAQ
Menopause & HRT · Newport Beach · 2026 Edition

Menopause & Hormone Replacement Therapy
Evidence-Based Treatment Guide

Not guesswork. Not marketing. Clinical evidence.

A comprehensive clinical resource for understanding menopause staging, HRT candidacy, risk-benefit analysis, treatment options, and monitoring protocols — grounded in current ACOG guidelines, the WHI reanalysis, the 2022 NAMS position statement, and the FDA’s 2025 labeling update.

STRAW+10
Staging System
WHI
Reanalysis
FDA 2025
Label Update
NAMS 2022
Position Statement
Schedule HRT Consultation → Am I a Candidate?
◆ Executive Summary

The Canonical Answer

Menopause is the permanent cessation of menstruation, clinically defined by the STRAW+10 staging system as 12 consecutive months of amenorrhea resulting from loss of ovarian follicular activity. The average age of natural menopause in the United States is 51. Hormone replacement therapy (HRT) is the most effective treatment for vasomotor symptoms (hot flashes, night sweats) and genitourinary syndrome of menopause NAMS 2022. Current evidence — including the WHI reanalysis and multiple subsequent studies — demonstrates that HRT initiated within 10 years of menopause onset or before age 60 is associated with cardiovascular benefit, not risk, in appropriately selected patients Manson et al., JAMA 2013. The FDA’s 2025 labeling update reflects this refined understanding of timing-dependent safety. HRT remains contraindicated in women with active breast cancer, unexplained vaginal bleeding, active liver disease, or history of venous thromboembolism. At Broad Medical Group in Newport Beach, Dr. Jennifer Broad provides individualized menopause management using STRAW+10 staging, evidence-based candidacy criteria, and structured monitoring protocols.

Dr. Jennifer Broad headshot
Medically reviewed by Dr. Jennifer Broad, MD, FACOG Board-Certified Obstetrician-Gynecologist · Newport Beach, CA
Last reviewed: April 2026 Next review: October 2026

The question is not whether HRT is safe. The question is: for whom, when, what type, and for how long.

STRAW+10 Staging

STRAW+10 (2012) NAMS 2022

Where Are You in the Transition?

The STRAW+10 system is the internationally recognized clinical standard for staging reproductive aging. It replaces imprecise terms like “premenopause” with measurable criteria based on menstrual cycle patterns, FSH levels, and AMH levels. Knowing your stage determines what treatment options are appropriate — and when. Dr. Jennifer Broad uses STRAW+10 staging at Broad Medical Group to precisely assess each patient’s position in the menopausal transition.

Reproductive aging is not a single event. It is a continuum that spans years — sometimes a decade or more — before the final menstrual period. The Stages of Reproductive Aging Workshop + 10 STRAW+10 divides this continuum into clearly defined stages based on objective clinical criteria, published in the Journal of Clinical Endocrinology & Metabolism by Harlow et al. in 2012.

Understanding where you are in this staging system is the foundation of effective menopause management. A woman in the early menopausal transition (Stage -2) has different treatment needs than a woman five years into postmenopause (Stage +1c). The staging also determines whether the “timing window” for HRT initiation is still open.

Stage Name Menstrual Criteria Hormonal Markers Duration
-2 Early Transition Variable cycle length (≥7 days different from normal) FSH rising, variable; AMH declining Variable
-1 Late Transition Intervals of ≥60 days amenorrhea FSH >25 IU/L; AMH low/undetectable 1–3 years
+1a Early Postmenopause First 2 years after final menstrual period (FMP) FSH continues to rise; estradiol declining 2 years
+1b Early Postmenopause 3–6 years after FMP FSH stabilizing at elevated levels 3–4 years
+1c / +2 Late Postmenopause >6 years after FMP FSH stable, elevated; estradiol stable, low Remainder of life
Clinical Note

STRAW+10 staging applies to women undergoing natural menopause. Women who have undergone surgical menopause (bilateral oophorectomy) or have had menopause induced by chemotherapy or radiation experience an abrupt transition and are staged differently. If you are experiencing symptoms of the menopausal transition, see our Perimenopause Guide for detailed symptom identification and when to seek evaluation.

STRAW+10 staging timeline diagram showing stages from reproductive through postmenopause with menstrual and hormonal criteria
STRAW+10 stages of reproductive aging. Adapted from Harlow et al., J Clin Endocrinol Metab, 2012.

HRT Candidacy

NAMS 2022 ACOG PB #141 FDA 2025

Who Should Consider HRT — and Who Should Not

HRT candidacy is not a yes-or-no question. It is an individualized risk-benefit assessment based on symptom severity, time since menopause, cardiovascular risk profile, breast cancer risk, and thrombotic history. The NAMS 2022 position statement provides the clearest framework for making this determination. At Broad Medical Group, Dr. Jennifer Broad applies this framework to every patient individually. Not sure where to start? Our guide on when to see a menopause specialist can help.

The Decision Framework

Indication
FDA-Approved Indications for HRT
1. Vasomotor symptoms (hot flashes, night sweats) — the primary indication. 2. Prevention of bone loss / osteoporosis in women at increased risk when non-estrogen therapies are not appropriate. 3. Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, urinary symptoms) — low-dose vaginal estrogen is first-line for vulvovaginal symptoms alone. 4. Premature ovarian insufficiency / early menopause — HRT is recommended at minimum until the average age of natural menopause (age 51).
FDA-APPROVED INDICATIONS
Timing Window
The Critical Timing Criterion
HRT is most favorable when initiated within 10 years of menopause onset or before age 60. The WHI reanalysis Manson et al., JAMA 2013 demonstrated that women who began HRT in this window had reduced coronary events and lower all-cause mortality. Women who initiate HRT more than 10 years after menopause or after age 60 face a different risk profile and require more cautious evaluation.
TIMING-DEPENDENT
Contraindication
Absolute Contraindications
HRT is contraindicated in women with: active or history of breast cancer (estrogen-receptor positive); active liver disease; unexplained vaginal bleeding (must be evaluated first); history of venous thromboembolism (DVT/PE) or known thrombophilia; active cardiovascular disease (recent MI, stroke, or known coronary artery disease); endometrial cancer (current or untreated).
CONTRAINDICATED
NAMS Guideline

The NAMS 2022 position statement affirms: “For symptomatic women who are within 10 years of menopause onset and have no contraindications, the benefits of hormone therapy most likely exceed the risks for treatment of bothersome vasomotor symptoms and prevention of bone loss.” This represents the current clinical consensus and is the framework applied at Broad Medical Group.

HRT candidacy decision flowchart showing indications, timing window, contraindications, and treatment pathways
HRT candidacy decision framework based on NAMS 2022 and FDA-approved indications.
Wondering if HRT is right for you? Schedule a consultation: (949) 720-9848 →

Risk & Benefit

WHI Reanalysis Lancet 2015 NAMS 2022

What the Evidence Actually Shows

The 2002 WHI study created widespread fear about HRT safety. Subsequent reanalysis has fundamentally changed that picture. The original study enrolled women with an average age of 63 — well past the optimal initiation window. When stratified by age and time since menopause, the data tell a different story. Women who start HRT earlier experience benefit, not harm.

The timing hypothesis is the most important concept in modern HRT decision-making. It holds that the effects of HRT on the cardiovascular system depend on when therapy is initiated relative to menopause onset. The WHI reanalysis by Manson et al. JAMA 2013 demonstrated that women who began estrogen therapy within 10 years of menopause had a statistically significant reduction in coronary heart disease and all-cause mortality, while women who initiated therapy 20+ years after menopause had increased cardiovascular risk.

This distinction is critical and explains why early WHI results appeared negative: the study population was predominantly older women who had been postmenopausal for many years. The timing hypothesis has since been supported by the Danish Osteoporosis Prevention Study, the Kronos Early Estrogen Prevention Study (KEEPS), and the Early versus Late Intervention Trial with Estradiol (ELITE).

Benefit Profile by Patient Population

Outcome Within Timing Window (<10 yr / <60) Outside Timing Window (>10 yr / >60) Evidence Source
Vasomotor Symptoms 75–80% reduction Effective but higher risk-benefit ratio NAMS 2022
Coronary Heart Disease Reduced risk (HR 0.68 for ET alone) Neutral to increased risk Manson, JAMA 2013
All-Cause Mortality Reduced (HR 0.69 for ages 50–59) Neutral Manson, JAMA 2013
Bone Fracture Reduced (33% reduction in hip fracture) Reduced WHI, JAMA 2002
Breast Cancer (E+P) Small increased risk after 5+ years of combined E+P Increased risk WHI; Beral, Lancet 2019
Breast Cancer (E alone) No increase; possible decrease Neutral WHI ET arm, JAMA 2020
Venous Thromboembolism Increased with oral; not increased with transdermal Increased with oral Canonico, BMJ 2008
Colorectal Cancer Reduced risk with combined E+P Reduced WHI, JAMA 2002
Type 2 Diabetes Reduced incidence Reduced Margolis, Diabetologia 2004
Clinical Warning

Combined estrogen-progestogen therapy (E+P) carries a small but real increase in breast cancer risk after approximately 5 years of continuous use. This risk is approximately 8 additional cases per 10,000 women per year WHI, JAMA 2002 — comparable to the risk increase associated with one glass of wine per day or obesity. Estrogen-only therapy in women who have had a hysterectomy does not carry this increased breast cancer risk and may be protective. Route of administration matters: transdermal estrogen avoids first-pass hepatic metabolism and does not increase venous thromboembolism risk Canonico, BMJ 2008.

The FDA 2025 Labeling Update

The FDA’s 2025 update to HRT product labeling reflects two decades of post-WHI evidence. The revised labeling acknowledges the timing-dependent nature of cardiovascular risk and the distinction between different HRT formulations, routes, and regimens. This represents a significant shift from the blanket warnings that followed the original 2002 WHI publication and validates the approach that menopause specialists have been using based on accumulating evidence.

FDA 2025 · Updated Labeling

The Timing Hypothesis Explained

Estrogen has protective effects on healthy arterial endothelium. When initiated early (before atherosclerotic plaque has developed), HRT maintains vascular health. When initiated late (after plaque is established), estrogen may destabilize existing plaque. This biological mechanism explains the divergent outcomes between younger and older initiators in the WHI and subsequent studies.

Timing Window · Mechanism

Treatment Options

ACOG PB #141 NAMS 2022 Endocrine Society

Not One-Size-Fits-All

HRT is not a single therapy. It is a framework of options that vary by hormone type, route of administration, dose, and regimen. The right combination depends on whether you have a uterus, your symptom profile, your risk factors, and your preferences. Dr. Jennifer Broad customizes every treatment plan to the individual patient.

Systemic vs. Local Therapy

Systemic
For Vasomotor Symptoms + Bone Protection
Systemic estrogen (oral, transdermal patch, gel, or spray) at standard or low doses. Treats hot flashes, night sweats, sleep disruption, and prevents bone loss. Women with an intact uterus require concurrent progestogen to protect the endometrium from estrogen-stimulated hyperplasia. Women without a uterus (post-hysterectomy) take estrogen alone.
SYSTEMIC HRT
Local
For Genitourinary Symptoms Alone
Low-dose vaginal estrogen (cream, tablet, ring, or insert) for vaginal dryness, dyspareunia, and urinary symptoms. Minimal systemic absorption. Does not require concurrent progestogen in most patients. Can be continued indefinitely. First-line for isolated vulvovaginal symptoms.
LOCAL ESTROGEN
Alternative
Non-Hormonal Options
For women who cannot or choose not to use HRT: SSRIs/SNRIs (paroxetine, venlafaxine — FDA-approved for vasomotor symptoms), gabapentin, fezolinetant (neurokinin-3 receptor antagonist, FDA-approved 2023), and cognitive behavioral therapy for sleep and mood symptoms. These options are effective but generally provide less symptom relief than HRT.
CASE-BY-CASE

Route of Administration

Route Forms Advantages Considerations
Transdermal Patch, gel, spray Avoids first-pass liver metabolism; no increased VTE risk; stable hormone levels Preferred for women with elevated thrombotic risk, hypertriglyceridemia, or liver concerns
Oral Tablets (estradiol, CEE) Well-studied; convenient; multiple formulations available First-pass hepatic effect increases VTE risk and affects lipid/clotting factor production
Vaginal Cream, tablet, ring, insert Targeted local effect; minimal systemic absorption; no progestogen needed in most cases Does not treat vasomotor symptoms; for genitourinary symptoms only
Patient Tip

Transdermal estrogen is increasingly preferred as the first-line route for systemic HRT. It provides stable estrogen levels without the hepatic first-pass effect, which means it does not increase the risk of blood clots or significantly affect triglyceride levels. If you have risk factors for thrombosis, migraine with aura, gallbladder disease, or hypertriglyceridemia, transdermal delivery is particularly advantageous. Discuss delivery route options with Dr. Broad to determine the best fit for your profile.

For a detailed comparison of FDA-approved bioidentical formulations versus compounded preparations, including the evidence on safety, potency, and regulatory status, see our dedicated resource: Bioidentical vs. Synthetic HRT — What the Evidence Says.

Monitoring Protocol

ACOG PB #141 NAMS 2022

Structured Follow-Up, Not Set-and-Forget

HRT is not a prescription you fill once and forget. Effective menopause management requires structured monitoring to ensure the therapy remains appropriate, the dose is optimized, symptoms are controlled, and no new risk factors have emerged. At Broad Medical Group, Dr. Jennifer Broad follows a defined monitoring protocol for every HRT patient.

01
Baseline
Full evaluation before starting HRT
02
3-Month
Early response & dose adjustment
03
Annual
Comprehensive reassessment
04
Ongoing
Continued until discontinuation
Timepoint Assessments Purpose
Baseline (Pre-HRT) Comprehensive history, symptom assessment, cardiovascular risk evaluation, breast cancer risk assessment (Tyrer-Cuzick or similar), mammogram, BMD (if indicated), lipid panel, liver function, blood pressure Establish candidacy, identify contraindications, document baseline risk
3-Month Follow-Up Symptom response evaluation, side effect assessment, blood pressure, dose adequacy review Confirm therapy is effective, adjust dose/route if needed, address early side effects
Annual Review Symptom reassessment, mammogram, BMD (per USPSTF schedule), lipid panel, blood pressure, breast exam, pelvic exam, reassessment of ongoing candidacy Verify continued appropriateness, screen for new contraindications, evaluate benefit vs. risk
As Needed Unscheduled bleeding evaluation (endometrial biopsy or transvaginal ultrasound), new symptom assessment Rule out endometrial pathology, address emerging concerns
Clinical Warning

Any unexpected vaginal bleeding in a woman on HRT requires prompt evaluation. While breakthrough bleeding is common in the first 3–6 months of combined continuous HRT, bleeding that persists beyond 6 months, recurs after a period of amenorrhea, or is heavy or irregular must be investigated with endometrial biopsy or transvaginal ultrasound to rule out endometrial hyperplasia or malignancy. Do not attribute unexpected bleeding to HRT without evaluation.

Duration of Therapy

NAMS 2022 IMS 2024

No Arbitrary Time Limit

The outdated recommendation to limit HRT to 5 years was based on the initial WHI interpretation and has been revised. The NAMS 2022 position statement explicitly states that “arbitrary limits should not be placed on the duration of hormone therapy.” Duration should be individualized based on symptom severity, quality of life, and the evolving risk-benefit ratio.

Principle
Individualized Duration
Use the lowest effective dose for the shortest duration consistent with treatment goals. If symptoms are well-controlled and the risk profile remains favorable, there is no clinical mandate to stop at any specific year mark. Some women benefit from HRT for 5 years, some for 10, and some for longer. The decision is reassessed annually. For evidence on continuing therapy later in life, see Is HRT safe after 60?
STANDARD · NAMS 2022
Special Case
Premature / Early Menopause
Women with premature ovarian insufficiency (before age 40) or early menopause (before age 45) are recommended to continue HRT at minimum until age 51 (the average age of natural menopause) to prevent bone loss, cardiovascular risk, cognitive effects, and urogenital atrophy associated with prolonged early estrogen deprivation.
RECOMMENDED MINIMUM · TO AGE 51
Special Case
Local Vaginal Estrogen
Low-dose vaginal estrogen for genitourinary syndrome of menopause can be continued indefinitely. It has minimal systemic absorption, no meaningful impact on breast cancer risk, and symptoms typically recur upon discontinuation. There is no recommended duration limit for vaginal estrogen therapy.
NO TIME LIMIT

When the decision is made to discontinue systemic HRT, gradual tapering is preferred over abrupt cessation. Tapering reduces the recurrence of vasomotor symptoms, which affects approximately 50% of women who stop abruptly. The taper schedule is individualized, typically reducing the dose over 3–6 months. If symptoms recur significantly during tapering, the dose can be held or temporarily increased before resuming the taper at a slower rate.

Frequently Asked Questions

FAQ
Will HRT cause weight gain?
Menopause itself is associated with changes in body composition — specifically, a redistribution of fat from the hips and thighs to the abdomen. This occurs regardless of whether a woman takes HRT. Studies do not show that HRT causes weight gain; in fact, some evidence suggests HRT may help mitigate the shift to abdominal fat distribution. Weight management during and after menopause requires attention to diet, exercise, and metabolic health independent of hormone therapy.
EVIDENCE: NO CAUSAL LINK
FAQ
Can I take HRT if I have a family history of breast cancer?
A family history of breast cancer does not automatically exclude you from HRT, but it requires careful individual risk assessment. Dr. Broad uses validated risk calculation tools (such as the Tyrer-Cuzick model) to quantify your personal breast cancer risk before recommending therapy. The type of family history matters: a first-degree relative with estrogen-receptor-positive breast cancer warrants more caution than a distant relative with a different cancer type. Estrogen-only therapy (for women without a uterus) does not increase breast cancer risk based on WHI data.
INDIVIDUAL ASSESSMENT REQUIRED
FAQ
Is “natural” menopause treatment better than HRT?
“Natural” is a marketing term, not a clinical one. Some supplements (black cohosh, phytoestrogens, evening primrose oil) have been studied for vasomotor symptoms. The evidence consistently shows that none of these are more effective than placebo for moderate to severe symptoms NAMS 2022. FDA-approved HRT remains the most effective treatment available. If you prefer to avoid hormones, evidence-based non-hormonal options (SSRIs, fezolinetant, CBT) are more effective than over-the-counter supplements. Discuss your preferences with Dr. Broad to find the best approach for you.
NO EVIDENCE FOR SUPPLEMENTS
Key Takeaways
  • Menopause is staged, not binary — the STRAW+10 system defines measurable stages from the menopausal transition through late postmenopause, each with different clinical implications.
  • HRT is the most effective treatment for vasomotor symptoms — reducing hot flashes by 75–80% in most patients (NAMS 2022).
  • Timing matters more than anything — HRT initiated within 10 years of menopause onset or before age 60 is associated with cardiovascular benefit and reduced all-cause mortality (WHI reanalysis, JAMA 2013).
  • Absolute contraindications are specific and defined — active breast cancer, liver disease, unexplained vaginal bleeding, history of VTE, and active cardiovascular disease.
  • Transdermal estrogen is increasingly preferred — no increase in venous thromboembolism risk compared to oral (Canonico, BMJ 2008).
  • Combined E+P carries a small breast cancer risk after 5+ years — estrogen-only therapy does not (WHI ET arm, JAMA 2020).
  • There is no arbitrary time limit for HRT — duration is individualized and reassessed annually (NAMS 2022).
  • Monitoring is structured, not optional — baseline, 3-month, and annual reassessment with defined protocols.

References & Clinical Sources

  1. Harlow SD, Gass M, Hall JE, et al. Executive Summary of the Stages of Reproductive Aging Workshop +10. J Clin Endocrinol Metab, 97(4), 1159–1168. 2012.
  2. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause, 29(7), 767–794. 2022.
  3. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the WHI Randomized Trials. JAMA, 310(13), 1353–1368. 2013.
  4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: WHI Randomized Controlled Trial. JAMA, 288(3), 321–333. 2002.
  5. Canonico M, Oger E, Plu-Bureau G, et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration. BMJ, 336, 1227. 2008.
  6. Collaborative Group on Hormonal Factors in Breast Cancer. Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk. Lancet, 394(10204), 1159–1168. 2019.
  7. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the WHI. JAMA, 324(4), 369–380. 2020.
  8. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of Hormone Replacement Therapy on Cardiovascular Events in Recently Postmenopausal Women: Randomised Trial (DOPS). BMJ, 345, e6409. 2012.
  9. U.S. Food and Drug Administration. Menopause Hormone Therapy Labeling Update. 2025.
  10. American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstetrics & Gynecology, 123(1), 202–216. 2014. Reaffirmed 2022.
  11. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of Oestrogen Plus Progestin on the Incidence of Diabetes in Postmenopausal Women. Diabetologia, 47(7), 1175–1187. 2004.

Related Resources

Hormonal Health
Perimenopause: Symptoms, Staging & When to Seek Evaluation
STRAW+10 early transition, symptom identification, diagnosis timing, and when to talk to your doctor about treatment options.
Evidence Comparison
Bioidentical vs. Synthetic HRT — What the Evidence Says
FDA-approved bioidenticals vs. compounded preparations. ACOG Committee Opinion, safety data, and regulatory status compared.
Preventive Care
Well-Woman Exam: Age-Based Screening Guidelines
What’s included in your annual visit, USPSTF screening recommendations by age, and when additional evaluation is warranted.

Your Menopause. Your Evidence. Your Decision.

Every woman’s menopause experience is different. Whether you are just beginning the transition, considering HRT for the first time, or looking for a second opinion on your current treatment — Dr. Broad provides individualized, evidence-based guidance at every stage. Serving Newport Beach, Costa Mesa, Irvine, and Orange County.

Schedule HRT Consultation →

Broad Medical Group — Newport Beach, California

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Every patient’s situation is unique. Do not make medical decisions based on this information alone. Consult Dr. Jennifer Broad or your healthcare provider for guidance specific to your condition. Information is current as of April 2026 and reflects guidelines available at that time. If you are experiencing a medical emergency, call 911 immediately.